Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FULC

Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results

Fulcrum Therapeutics Inc. (NASDAQ:FULC) stock is surging on Monday, after the company released initial results from the ongoing 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease.

Benzinga · Dec 8, 2025

3 High-Potential Biotech Stocks Under $10

The biotech industry is witnessing rapid growth owing to its increasing demand and the inclusion of technological advancements. In this wake, investors could consider adding pocket-friendly biotech stocks Fulcrum Therapeutics (FULC), BioCryst Pharmaceuticals (BCRX), and Precision BioSciences (DTIL) to their portfolio. Continue to read….

StockNews.com · Aug 27, 2024

4 Analysts Have This to Say About Fulcrum Therapeutics

Within the last quarter, Fulcrum Therapeutics (NASDAQ:FULC) has observed the following analyst ratings:

Benzinga · Jun 13, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Mid-Afternoon Market Update: Dow Drops Over 600 Points; Fulcrum Therapeutics Shares Tumble

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 600 points on Friday.

Benzinga · Jun 10, 2022

Looking Into Fulcrum Therapeutics's Return On Capital Employed

Benzinga Pro data, Fulcrum Therapeutics (NASDAQ:FULC) reported Q1 sales of $2.59 million. Earnings fell to a loss of $25.93 million, resulting in a 10.41% decrease from last quarter.

Benzinga · Jun 3, 2022

Earnings Preview: Fulcrum Therapeutics

Fulcrum Therapeutics (NASDAQ:FULC) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Fulcrum Therapeutics will report an earnings per share (EPS) of $-0.63.

Benzinga · May 6, 2022

Fulcrum Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know

Fulcrum Therapeutics (NASDAQ:FULC) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.

Benzinga · May 4, 2022

Read news from The Economist, FT, and more,
with one subscription

Fulcrum Therapeutics's Return On Capital Employed Overview

Benzinga Pro data, Fulcrum Therapeutics (NASDAQ:FULC) reported Q4 sales of $5.06 million. Earnings fell to a loss of $23.48 million, resulting in a 13.36% decrease from last quarter.

Benzinga · Mar 9, 2022

Fulcrum Therapeutics To Start Late-Stage Losmapimod Trial In Rare Muscle Wasting Disorder

Fulcrum Therapeutics Inc (NASDAQ: FULC) plans to initiate REACH, a Phase 3 trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD),

Benzinga · Mar 3, 2022

Fulcrum Therapeutics: Q4 Earnings Insights

Fulcrum Therapeutics (NASDAQ:FULC) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · Mar 3, 2022

Earnings Preview For Fulcrum Therapeutics

Fulcrum Therapeutics (NASDAQ:FULC) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate that Fulcrum Therapeutics will report an earnings per share (EPS) of $-0.73.

Benzinga · Mar 2, 2022

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

424,518 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.